Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Tarsus Pharmaceuticals Inc. (TARS)

NASDAQ: TARS · Biological Products, (No Diagnostic Substances) · Irvine, CA

Our rating: Positive

Call changed from Cautious to Positive at $69.07, moderate conviction, November 4, 2026.

Breaks if: The positive tilt is wrong if Tarsus reports year-over-year net revenue growth below 35% for two consecutive quarters through the end of 2027 — signaling that its lead product's penetration has plateaued faster than the current ramp implies — or if annual free cash flow burn widens beyond -$60M in any reported twelve-month period without a disclosed pipeline catalyst of comparable commercial scale to justify the step-up in spending. Either condition would indicate the valuation multiple has gotten ahead of a deteriorating growth or cash story.

Key figures

Market value$3.6B
Revenue, last 12 months$682M
Net income, last 12 months−$702M
Free cash flow, last 12 months$32M
Price to earningsn/a
Free cash flow yield0.9%
Dividend yield0.0%
Operating margin−102.0%
Return on equity−319.8%
Beta to the S&P 5000.58
Volatility, annualized50.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$195M63.9%$-14.40−$7M
June 30, 2026$174M69.4%$-0.43$57M
March 31, 2026$162M106.9%$-0.16−$30M
December 31, 2025$152M128.4%$-0.19$13M
September 30, 2025$119M146.7%$-0.30$16M
June 30, 2025$103M151.5%$-0.48−$30M
March 31, 2025$78M183.7%$-0.64−$21M
December 31, 2024$66M407.9%$-0.59−$22M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

15 ledger entries and 24 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.